These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Hainsworth JD; Infante JR; Spigel DR; Arrowsmith ER; Boccia RV; Burris HA Cancer Invest; 2011 Aug; 29(7):451-5. PubMed ID: 21696296 [TBL] [Abstract][Full Text] [Related]
26. Treatment of muscular dystrophies. Kingston WJ; Moxley RT Gen Pharmacol; 1989; 20(3):263-8. PubMed ID: 2663627 [TBL] [Abstract][Full Text] [Related]
27. Histone deacetylase inhibitors: a review on class-I specific inhibition. Behera J; Jayaprakash V; Sinha BN Mini Rev Med Chem; 2015; 15(9):731-50. PubMed ID: 25994050 [TBL] [Abstract][Full Text] [Related]
28. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma. Cheng T; Grasse L; Shah J; Chandra J Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387 [TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase inhibitor trichostatin A synergistically resensitizes a cisplatin resistant human bladder cancer cell line. Yoon CY; Park MJ; Lee JS; Lee SC; Oh JJ; Park H; Chung CW; Abdullajanov MM; Jeong SJ; Hong SK; Byun SS; Lee ES; Lee SE J Urol; 2011 Mar; 185(3):1102-11. PubMed ID: 21255805 [TBL] [Abstract][Full Text] [Related]
31. The synergistic effect of panobinostat (LBH589) with melphalan or doxorubicin on multiple myeloma cells; rationale for the use of combination regimens in myeloma patients. Terpos E Leuk Res; 2011 Mar; 35(3):295-6. PubMed ID: 21093911 [No Abstract] [Full Text] [Related]
32. [Histone deacetylase inhibitors: new synergistic third-line option in multiple myeloma]. Stegmann DA Med Monatsschr Pharm; 2016 Apr; 39(4):142-7. PubMed ID: 27209894 [TBL] [Abstract][Full Text] [Related]
33. Emerging role of histone deacetylase inhibitors as anti-breast-cancer agents. Ediriweera MK; Tennekoon KH; Samarakoon SR Drug Discov Today; 2019 Mar; 24(3):685-702. PubMed ID: 30776482 [TBL] [Abstract][Full Text] [Related]
34. In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers. Maschauer S; Gahr S; Gandesiri M; Tripal P; Schneider-Stock R; Kuwert T; Ocker M; Prante O Nucl Med Biol; 2016 Jan; 43(1):27-34. PubMed ID: 26702784 [TBL] [Abstract][Full Text] [Related]
35. Beleodaq approved for rare lymphomas. Cancer Discov; 2014 Sep; 4(9):978. PubMed ID: 25185167 [TBL] [Abstract][Full Text] [Related]